Department of Pathology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206. doi: 10.1111/nan.12428. Epub 2017 Sep 5.
Glioblastomas are highly aggressive and treatment resistant. Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence.
Samples from 240 patients with primary glioma were stained with antibodies against ionized calcium-binding adaptor molecule-1 (IBA-1) and cluster of differentiation 204 (CD204) to detect TAMs and M2-like TAMs. The expression levels were quantified by software-based classifiers. The associations between TAMs, gemistocytic cells and glioblastoma subtype were examined with immuno- and haematoxylin-eosin stainings. Three tissue arrays containing glioblastoma specimens were included to study IBA-1/CD204 levels in central tumour and tumour periphery and to characterize CD204 cells.
Our data revealed that the amount of especially CD204 TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase. Our findings were confirmed in two bioinformatics databases. TAMs were more abundant in central tumour tissue, mesenchymal glioblastomas and gliomas with many gemistocytic cells. CD204 TAMs co-expressed proteins related to tumour aggressiveness including matrix metallopeptidase-14 and hypoxia-inducible factor-1α.
This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.
胶质母细胞瘤具有高度侵袭性和耐药性。越来越多的证据表明,肿瘤相关巨噬细胞/小胶质细胞(TAMs)通过获得 M2 样表型来促进肿瘤进展。我们的目的是使用自动化定量双免疫荧光法研究 TAMs 在胶质瘤中的预后价值。
对 240 例原发性脑胶质瘤患者的样本进行离子钙结合衔接分子-1(IBA-1)和分化群 204(CD204)抗体染色,以检测 TAMs 和 M2 样 TAMs。通过基于软件的分类器对表达水平进行定量。通过免疫和苏木精-伊红染色检查 TAMs、胶质母细胞瘤样细胞与胶质母细胞瘤亚型之间的关系。纳入三个包含胶质母细胞瘤标本的组织芯片,研究中央肿瘤和肿瘤边缘的 IBA-1/CD204 水平,并对 CD204 细胞进行特征描述。
我们的数据显示,特别是 CD204 TAMs 的数量随着恶性程度的增加而增加。在 3-4 级,高 CD204 表达与较短的生存期相关,而高 IBA-1 强度与较长的生存期相关。在 4 级中,在调整临床数据和 O6-甲基鸟嘌呤-DNA 甲基转移酶的甲基化状态后,CD204 显示出独立的预后价值。我们的发现在两个生物信息学数据库中得到了证实。TAMs 在中央肿瘤组织、间充质胶质母细胞瘤和有许多胶质母细胞瘤样细胞的胶质瘤中更为丰富。CD204 TAMs 共同表达与肿瘤侵袭性相关的蛋白质,包括基质金属蛋白酶-14 和缺氧诱导因子-1α。
这是第一项使用自动化定量免疫荧光法确定 TAMs 预后影响的研究。我们的结果表明,M2 样 TAMs 在高级别胶质瘤中具有不利的预后价值,并可能有助于促进肿瘤发生的微环境。